FDA Threatens Seizure Over ‘Copycat’ Weight Shots

FDA document with pills and a stethoscope on a wooden surface
Photo: bangoland / Shutterstock

The Food and Drug Administration told a leading compounder to stop making “copycat” GLP-1 shots in big volumes—or face seizure and injunction.

Story Snapshot

  • The Food and Drug Administration issued a formal warning letter to Empower Pharmacy over compounded GLP-1 drugs.
  • Officials said Empower’s tirzepatide and semaglutide mixes were essentially copies of approved drugs.
  • Inspectors cited insanitary sterile practices and quality-control failures at the facility.
  • The Food and Drug Administration gave 15 working days for a written fix plan or further action may follow.

What the Food and Drug Administration said and why it matters

The Food and Drug Administration sent Empower Clinic Services, doing business as Empower Pharmacy, a warning letter on September 18, 2026, after a November 2025 inspection.

The agency said Empower made compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin that still looked like copies of approved drugs, even with the added ingredients.

Officials also said the pharmacy produced these drugs in “inordinate amounts,” which clashes with the rules for individualized compounding under section 503A.

The Food and Drug Administration’s letter matters because it can strip exemptions. If a 503A pharmacy compounds products that are essentially copies, or in inordinate amounts, those drugs lose key legal protections.

They become unapproved and misbranded under the Federal Food, Drug, and Cosmetic Act, which opens the door to seizure and injunction. The agency’s action fits a broader push to remove copy products from the market once brand-name supply stabilizes and shortages end.

Safety red flags inside a sterile room

Inspectors reported problems with sterile operations that protect patients from contamination. Reports described gaps in smoke studies, media fills, environmental monitoring, aseptic technique, and production procedures. That list points to system issues, not a single bad day on the line.

The Food and Drug Administration has warned for months that compounded GLP-1 drugs are not reviewed for safety, effectiveness, or quality before they are sold, which raises risk if sterile controls are weak.

Americans deserve weight-loss options that are safe, clean, and what the label claims. When a pharmacy runs sterile rooms, the bar must be high every day, not just when an inspector visits.

The Food and Drug Administration’s focus on process may sound dull, but process is what keeps microbes out of a vial headed for your abdomen. That line separates help from harm.

The access squeeze: cheaper shots and a tighter lane

Many patients turned to compounded GLP-1s because list prices for brand drugs are high. Some videos and reports peg compounded options as low as double-digit dollars per month, far below the four-figure cost of approved products.

That price gap made compounded shots a lifeline for people on fixed incomes or with poor coverage. But the legal lane for compounding narrows once shortages clear, and the Food and Drug Administration has said copy versions must stop when supply returns.

The agency also clarified earlier this year that it does not plan to act if a compounder fills four or fewer prescriptions of an essentially copy product in a month, but larger runs draw scrutiny. That position aims to preserve true one-off patient needs, while shutting down mass production that looks like shadow manufacturing.

Patients should expect tighter access to cheap compounded GLP-1s as the rules bite. That shift will sting at the pharmacy counter, but it matches the law on copies and inordinate amounts.

What Empower says, and what comes next

Empower markets nationwide access to affordable compounded medicines and says it can serve patients with individual prescriptions from its section 503A pharmacy.

Company statements and commentary say leaders have worked with the Food and Drug Administration and remediated many issues, and supporters frame the fight as care versus commerce.

Those views stress access and patient choice, but they do not undo the legal bar on copy products made at scale under 503A.

The next steps are clear. Empower has 15 working days from the letter to explain fixes or face stronger action. Patients should talk with their doctors now about approved GLP-1 options, coverage appeals, and safe taper plans.

Lawmakers and insurers should press brand makers on transparent pricing and patient assistance. The right answer is not dirty rooms or legal gray markets; it is clean supply, honest labels, and prices families can bear without cutting safety corners.

Sources:

cbsnews.com, beckershospitalreview.com, medpagetoday.com, fda.gov, empowerpharmacy.com

RELATED ARTICLESMORE FROM AUTHOR

Focus Feature

© 2026 Go Real News Now.
All Rights Reserved.